Non-Steroidal Mineralocorticoid Receptor Antagonists: Finerenone and Others in Pipeline for Chronic Kidney Disease and Heart Failure
This presentation will cover new non-steroidal mineralocorticoid receptor antagonists (NSMRAs), both FDA approved and upcoming, for chronic kidney disease and heart failure.
It will feature an analysis of the major clinical trials investigating finerenone in patients with heart failure and patients with chronic kidney disease in the setting of type 2 diabetes, a review of the benefits that non-steroidal mineralocorticoid receptor antagonists offer over steroidal mineralocorticoid receptor antagonists, a comparison of the structure-activity relationship and medicinal chemistry between non-steroidal mineralocorticoid receptor antagonists and mineralocorticoid receptor antagonists, and a look into non-steroidal mineralocorticoid receptor antagonists currently undergoing clinical trials.
Target Audience
This course is intended for pharmacists
Learning Objectives
At the completion of this activity, the participant will be able to
- Appraise the risk of hyperkalemia associated with steroidal mineralocorticoid receptor antagonists
- Compare and contrast the structure-activity relationship of available steroidal and non-steroidal mineralocorticoid receptor antagonists
- Assess current guideline recommendations for NSMRA use in patients with heart failure and chronic kidney disease with type 2 diabetes
- Evaluate clinical trials for approved and upcoming non-steroidal mineralocorticoid receptor antagonists for patients with heart failure and patients with chronic kidney disease and type 2 diabetes.
Faculty
Michael Keeney, PharmD, PGY1 Pharmacy Resident - Aurora BayCare Medical Center
Disclosure
The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.
Accreditation Statement
In support of improving patient care, Advocate Aurora Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Accreditation Council for Pharmacy Education (ACPE)
Advocate Aurora Health designates this live activity for a maximum 1.00 hours of CPE credit for pharmacists. CPE credit can be claimed on the AAH CE platform within 60 days of activity completion and information will be provided to CPE Monitor. Participants should only claim credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 Continuing Pharmacy Education (CPE)Aurora Health Care Department of Pharmacy Services is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Price
Click “Take Course” to register for this program.
This conference is being held virtually. A link to the meeting will be provided prior to the event.
Contact the AAH Pharmacy Continuing Education team at AAH-PharmacyCPEsubmission@aah.org if you have any questions or need assistance.